Welcome!

to the American Academy of Addiction Psychiatry’s 33rd Annual Meeting and Scientific Symposium

On behalf of the AAAP Staff and Board of Directors, I would like to welcome you to the 33rd AAAP Annual Meeting and Scientific Symposium. After two years of meeting virtually, it will be a pleasure to see you all and meet in person. AAAP has always been a warm and welcoming organization with a collegial spirit that is unmatched. I hope everyone takes advantage of this wonderful opportunity to connect with old friends and network with colleagues. We have some fun and exciting events this year, but our top priority is making sure everyone stays healthy, which is why we are strongly encouraging masks inside.

If you’re a new member or early in your career, you’ll find the leadership willing to help and answer questions. Be sure to use the AAAP meeting app to find the latest announcements. Trainees should be sure to take advantage of access to leaders in the field during the Coffee Hour with the Experts. AAAP is a place where national leaders in Addiction Psychiatry are accessible and eager to meet attendees and provide opportunities to learn from one another.

I look forward to seeing all of you and am sure we will have a productive and enjoyable meeting!

Larissa Mooney, AAAP President
Table of Contents

About AAAP 3
Arts and Advocacy Award 4
Founders Award 5
Schedule at a Glance 6
Accreditation and Designation Statements 8
Symposia I 9
Symposia II 11
Symposia III 15
Workshops 17
Awards 18
What is AAAP?

AAAP is a professional membership organization founded in 1985 with more than 2,000 members. Membership includes Addiction Psychiatrists, general psychiatrists, primary care providers, nurses, pharmacists and those in training contributing to the field of substance use disorders and mental disorders.

- The leading professional membership organization for learning and sharing about the art and science of Addiction Psychiatry research and clinical treatment.
- Transforming lives through a commitment to using evidenced-based research to continually improve clinical approaches and outcomes of their patients.
- A caring and engaging group of like-minded professionals who are committed to translating work from the laboratory to providing effective treatment needed in the real world.
- A collegial environment where health professionals have the opportunity to see colleagues, make new friends, learn from thought leaders and contribute their own knowledge to an ever-expanding dialogue.
- An organization committed to providing an ideal forum to support building collaborative efforts among health professionals and to expand their skills through certification and continuing education programs in the field of Addiction Psychiatry.

As one of the most informative addiction conferences in the country, our annual meeting provides the latest scientific and clinical approaches in substance use disorders and mental disorders.

Get ready to:

- Learn the latest evidence-based information in Addiction Psychiatry through a wide variety of workshops and symposia.
- Meet the leading experts in the field of Addiction Psychiatry.
- Meet new friends and re-connect with colleagues.
- Learn while having fun!

www.aaap.org
Holding the Door Open: Building the Addiction Policy Workforce

Regina LaBelle, JD is a distinguished scholar and director of the Addiction and Public Policy Initiative at the O’Neill Institute at Georgetown University Law Center. LaBelle also founded, directs, and is a professor in the Master of Science in Addiction Policy and Practice program at Georgetown University’s Graduate School of Arts & Sciences.

LaBelle brings decades of public service to her work at Georgetown University. Most recently, she was appointed by the Biden-Harris administration to the position of Acting Director in the White House Office of National Drug Control Policy (ONDCP). There, LaBelle developed the Biden-Harris Administration’s drug policy priorities, which included a historic focus on harm reduction services. LaBelle previously served in the Obama Administration as ONDCP Chief of Staff where she oversaw the agency’s overdose response and implementation of the National Drug Control Strategy.

Prior to her work in federal government, LaBelle served as Legal Counsel to Seattle Mayor Greg Nickels, providing legal and policy advice to the Mayor. From 1998 to 2005, LaBelle was an adjunct professor of policy and ethics at the Seattle University Institute for Policy Studies. LaBelle is an active member of the Washington State Bar and serves on the World Anti-Doping Agency’s Independent Ethics Board.

A graduate of Boston College, LaBelle received her law degree from Georgetown University Law Center.
Shelly F. Greenfield, MD, MPH is Professor of Psychiatry at Harvard Medical School and the Kristine M. Trustey Endowed Chair of Psychiatry at McLean Hospital where she also serves as the Chief Academic Officer. She is the Chief of the Division of Women’s Mental Health and the Director of Clinical and Health Services Research and Education in the Alcohol, Drug and Addiction Treatment Program at McLean Hospital.

Dr. Greenfield is an addiction psychiatrist, clinician and researcher. Dr. Greenfield has served as Principal Investigator and Co-Investigator on federally funded research focusing on treatment for substance use disorders, gender differences in substance disorders, and health services for substance disorders. She received a National Institute on Drug Abuse (NIDA)-funded career award in substance use disorder patient oriented research (2005-2016). Funded by grants from NIH/NIDA, she developed and tested a new manual-based group therapy for women with substance use disorders, the Women's Recovery Group (WRG). The WRG is an evidence-based treatment and the manual for dissemination was published in 2016, Treating Women with Substance Use Disorders: The Women's Recovery Group Manual.

Dr. Greenfield is Past President of the American Academy of Addiction Psychiatry and current member and past chair of the American Psychiatric Association's Council on Addiction Psychiatry. She is immediate past Editor-in-Chief of the Harvard Review of Psychiatry, a position in which she served for 16 years (2002-2018). Dr. Greenfield was a member of the Advisory Committee on Services for Women for the U.S. Substance Abuse and Mental Health Services Administration (2011-2017) and is a member of the NIH/NIDA National Advisory Council on Drug Abuse (2021-2023). She has been elected to the American College of Psychiatrists and the College on Problems of Drug Dependence, and is a Distinguished Fellow of the American Psychiatric Association.

Dr. Greenfield received the R. Brinkley Smithers Distinguished Scientist Award from the American Society of Addiction Medicine, Harvard Medical School's A. Clifford Barger Award for Excellence in Mentoring, the Stuart A. Hauser Award for Mentoring from the Department of Psychiatry, and the 2022 Dean's Award for Community Service for the Mass General Brigham/McLean Hospital Outreach Program with Indian Health Service.
## Schedule at a Glance

### WEDNESDAY, DECEMBER 7
- **1:45 PM – 4:30 PM** Board of Directors Meeting
  Orchid I-II
- **2:00 PM – 9:00 PM** Registration
  Royal Palm Foyer

### THURSDAY, DECEMBER 8
- **8:00 AM – 6:00 PM** Registration
  Royal Palm Foyer
- **9:00 AM - 10:00 AM** Coffee/tea service
  Royal Palm Foyer
- **10:00 AM – 10:15 AM** Welcome Remarks and President’s Address
  Royal Palm IV-V
- **10:15 AM – 12:15 PM** Symposium I: Cannabis Policy: Misaligned with Science
  Royal Palm IV-V
- **12:15 PM – 1:30 PM** AAAP Committee and Interest Group Meetings
  Refer to App
- **12:15 PM – 1:30 PM** Lunch and Networking
  Vista Ballroom and Terrace
- **1:30 PM – 3:00 PM** Concurrent Workshop Session A
  Refer to App
- **3:00 PM - 3:15 PM** Break
  Royal Palm Foyer
- **3:15 PM – 4:30 PM** Case Conference: In-Hospital Substance Use and the Use of Civil Commitment for Substance Use Disorders
  Royal Palm IV-V
- **4:45 PM – 5:45 PM** Arts and Advocacy Award
  Royal Palm IV-V
- **6:00 PM - 7:00 PM** Welcome Reception and Committee Fair
  Sunset Veranda & Vista Terrace
- **7:30 PM – 8:30 PM** Area Directors’ Meeting
  Acacia II
- **8:00 PM** Trainees meet for mingle (on own)
  Meet at Hotel Entrance
- **9:00 PM – 10:00 PM** Recovery Meeting
  Acacia V

### FRIDAY, DECEMBER 9
- **6:30 AM – 7:30 AM** Wake Up with Yoga
  Naples Grande Spa
- **7:00 AM – 5:00 PM** Registration
  Royal Palm Foyer
- **7:00 AM – 8:00 AM** Coffee Hour and Networking
  Royal Palm Foyer
- **8:00 AM – 9:00 AM** Keynote Session: Founders’ Award
  Royal Palm IV-V
- **9:00 AM – 11:00 AM** Symposium II: Improving Outcome of Medication Treatment for Opioid Use Disorder: Predictive Modeling and the Potential for Adaptive Clinical Strategies
  Royal Palm IV-V
- **11:15 AM – 12:30 PM** Medical Update: Transgender Medicine
  Royal Palm IV-V
- **12:30 PM – 2:00 PM** Lunch and Networking
  Vista Ballroom and Terrace
- **12:45 PM – 2:00 PM** AAAP Committee and Interest Group Meetings
  Refer to App
- **2:00 PM – 3:30 PM** Concurrent Workshop Session B
  Refer to App
- **3:45 PM - 4:45 PM** Paper Session I
  Royal Palm VI-VIII
- **3:45 PM - 4:45 PM** Paper Session II
  Royal Palm I-III
- **3:45 PM - 4:45 PM** Paper Session III
  Orchid III-IV
- **4:45 PM – 6:45 PM** Film Workshop: We’re Not Making It Past 21: Juice WRLD, Hip Hop Culture, and Substance Use Disorders
  Royal Palm IV-V
- **6:45 PM – 7:45 PM** Fellowship Forum
  Royal Palm VI-VIII
- **9:00 PM - 10:00 PM** Recovery Meeting
  Acacia V
SATURDAY, DECEMBER 10
6:30 AM – 7:30 AM  Wake Up with Yoga       Naples Grande Spa
8:00 AM – 4:00 PM  Registration Open     Royal Palm Foyer
9:00 AM – 10:00 AM Beachside Chat with Breakfast Sunset Veranda
10:15 AM – 11:45 AM Concurrent Workshop Sessions C Refer to App
11:45 AM – 1:30 PM Lunch and Networking Vista Ballroom and Terrace
11:45 AM – 1:30 PM AAAP Committee and Interest Group Meetings Refer to App
1:30 PM – 3:30 PM  Symposium III: Inequities in Substance Use Treatment for Marginalized Communities: Challenges and Opportunities Royal Palm IV-V
3:30 PM – 4:30 PM  AAAP Area Meetings Refer to App
6:30 PM – 7:30 PM  Awards Ceremony Royal Palm IV-V
7:30 PM – 9:00 PM  Closing Reception Mangrove Pool
9:00 PM – 10:00 PM Recovery Meeting Acacia V
9:00 PM – 11:00 PM Trainee Soiree Hibiscus Pool

SUNDAY, DECEMBER 11
8:00 AM – 10:00 AM Coffee and Poster Walk Ballroom Foyers, Acacia I
10:00 AM          Conference Adjourns
Accreditation and Designation Statements

**Accreditation Statement**
In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

**Target Audience Statement**
This activity was designed for physicians and other healthcare professionals.

**Physician Designation Statement**
American Academy of Addiction Psychiatry designates this live activity for a maximum of 21 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Other Health Professionals Designation Statement**
Participants will receive a Certificate of Attendance stating this program is designated for 21 AMA PRA Category 1 Credits™. This credit is accepted by the AANP and the AAPA.

**Credits subject to change.**
Cannabis Policy: Misaligned with Science?

Thursday, December 8, 2022, 10:15 AM - 12:15 PM

With cannabis becoming more readily available in the United States, psychiatrists need to have the most updated information available on cannabis and cannabinoids in order to help patients make informed decisions. Although 37 states have medical cannabis laws in place, many qualifying conditions have limited evidence demonstrating the efficacy of cannabinoids as pharmacotherapy. For example, while several state medical cannabis programs have now allowed for addiction as a qualifying condition for access to medical cannabis, the scientific literature is mixed on potential effectiveness of cannabis and derivative products for reducing other substance use. Legalization has had a profound effect upon cannabis markets in the United States; this has wide-reaching implications for clinicians and patients alike. We will also discuss approaches that clinicians may take in their practices which may increase the likelihood of their patients receiving evidence-based treatments, whether or not those treatments include cannabinoids.

Kevin Hill, M.D., Chairperson and Presenter

Dr. Kevin Hill is Director of Addiction Psychiatry at Beth Israel Deaconess Medical Center (BIDMC) an Associate Professor of Psychiatry at Harvard Medical School. He Earned a Master’s in Health Science at the Robert Wood Johnson Clinical Scholars Program at the Yale School of Medicine. He most commonly treats patients who have problems with alcohol, cannabis, or opioids and has been named one of Boston Magazine’s Top Doctors for the past four years. He teaches medical students and physicians how to treat patients with addictions. He treats professional athletes from the National Football League (NFL), the National Basketball Association, and the Boston Red Sox, as well as airline pilots. He consults to the NFL and is the Co-Chair of the NFL/NFL Players’ Association Pain Management Committee. The author of Marijuana: The Unbiased Truth About the World’s Most Popular Weed (Hazelden 2015) and Co-Author of Medical Cannabis: An Evidence-Based Guide (Wolters-Kluwer 2020). Dr. Hill’s research interests include the development of medications to treat cannabis use disorder as well as cannabis policy, and he has published widely on these topics in such journals as JAMA, The American Journal of Psychiatry, JAMA Internal Medicine, and Lancet Psychiatry. He serves on the editorial boards of Cannabis and Cannabinoid Research and the American Journal on Addictions.
Rosalie Liccardo Pacula is the current President of the International Society for the Study of Drug Policy and holds the Elizabeth Garrett Chair in Health Policy, Economics & Law in the Sol Price School of Public Policy at the University of Southern California. She holds a Doctorate in economics, focusing her research on issues related to drug markets and the factors influencing demand and supply for both licit and illicit intoxicating substances. She has been the lead investigator on several NIH studies examining the impact of state marijuana liberalization policies (decriminalization, medicalization and legalization) and opioid policies (those targeting treatment, supply reduction and harm reduction). Her groundbreaking work in this area has led to her invitation to serve on NIDA’s National Advisory Council Cannabis Policy Workgroup (2017), the Substance Abuse and Mental Health Services Administration (SAMHSA’s) Technical Advisory Committee on Preventing Cannabis Use among Youth (2020-Present), the World Health Organization’s Technical Expert Committee on Cannabis Use and Cannabis Policy (December 2019-Present), and the CDC’s National Injury Prevention’s Board of Scholarly Counsellors (2021- Present).

Smita Das, M.D., Ph.D., M.P.H., Presenter

Smita Das is Board Certified in Psychiatry, Addiction Psychiatry and Addiction Medicine. Dr. Das studied Chemistry and Statistics at Stanford, completed her Masters in Public Health at Dartmouth College, and then completed her MD/PhD in Community Health at the University of Illinois in Urbana Champaign. She completed psychiatry residency and was chief resident at Stanford followed by an addiction psychiatry fellowship at UCSF. She has over 2 decades of experience in research in healthcare quality and addiction. Dr. Das has an appointment to the APA Addiction Council. She has been a leader in the Northern California Psychiatric Society since 2012 and is a Past President of the APA District Branch. Prior to her position as Medical Director of Psychiatry at Lyra Health, Dr. Das was Director of Addiction Treatment Services at the Palo Alto VA. In addition to her work at Lyra, Dr. Das practices in addictions at Stanford School of Medicine where she is a Clinical Associate Professor.

Rosalie Pacula, Ph.D., Presenter

Rosalie Liccardo Pacula is the current President of the International Society for the Study of Drug Policy and holds the Elizabeth Garrett Chair in Health Policy, Economics & Law in the Sol Price School of Public Policy at the University of Southern California. She holds a Doctorate in economics, focusing her research on issues related to drug markets and the factors influencing demand and supply for both licit and illicit intoxicating substances. She has been the lead investigator on several NIH studies examining the impact of state marijuana liberalization policies (decriminalization, medicalization and legalization) and opioid policies (those targeting treatment, supply reduction and harm reduction). Her groundbreaking work in this area has led to her invitation to serve on NIDA’s National Advisory Council Cannabis Policy Workgroup (2017), the Substance Abuse and Mental Health Services Administration (SAMHSA’s) Technical Advisory Committee on Preventing Cannabis Use among Youth (2020-Present), the World Health Organization’s Technical Expert Committee on Cannabis Use and Cannabis Policy (December 2019-Present), and the CDC’s National Injury Prevention’s Board of Scholarly Counsellors (2021- Present).
Symposium I (continued)

Arthur Robin Williams, M.D., Presenter

Dr. Williams is Assistant Professor of Psychiatry, Columbia University Division on Substance Use Disorders. Dr. Williams receives NIDA and SAMHSA funding to develop a quality of care framework, the OUD Cascade of Care, to respond to the opioid crisis as well research into medical cannabis policy and uses of cannabinoids. Dr. Williams also serves as the Director of AAAP Region II (New York).

Symposium II

Improving Outcome of Medication Treatment for Opioid Use Disorder: Predictive Modeling and the Potential for Adaptive Clinical Strategies

Friday, December 9, 2022, 9:00 AM – 11:00 AM

Medication treatment of Opioid Use Disorder (OUD) is challenging because of high rates of relapse and drop-out. Clinicians initiate medication treatment and adapt treatment (dose, visit frequency, concurrent psychosocial interventions) reactively based on clinical rules of thumb. What if an algorithm were available, analogous to a credit score, that could predict the risk of relapse prospectively based on patient characteristics at baseline? This Symposium will present data from a large, harmonized dataset from 3 clinical trials of methadone, buprenorphine, and extended-release injection naltrexone (XR-NTX; aka Vivitrol), conducted in the NIDA Clinical Trials Network, used to create such predictive models. Dr. Luo will present a predictive model that can estimate the risk of relapse at the end of 3 months of treatment, from simple baseline clinical characteristics and/or outcome during the first few weeks of treatment. This model is now disseminated through a web portal that is easy to use for clinicians. Dr. Brandt will present data quantifying the risk of overdose events. Dr. Odom will discuss methodological issues in the development of predictive models and outcome selection that clinicians should understand in the 2022 AAAP Annual Meeting and Scientific Symposium interpreting such models. Dr. Springer will present recently completed clinical trials of XR-NTX in criminal justice populations and discuss the challenges of adapting treatment given the social determinants complicating treatment in such populations. Dr. Nunes will follow with a comment and summary, followed by moderated, audience-interactive discussion. The symposium will address questions around adaptive treatment strategies to improve outcome of treatment for opioid use disorder.

Sean Luo, M.D., Ph.D., Chairperson and Presenter

Dr. Luo is Assistant Professor of Clinical Psychiatry, Columbia University Division on Substance Use Disorders, and Research Scientist, New York State Psychiatric Institute. He attended University of Chicago for his undergraduate degree in physics and mathematics and completed his training through the Medical Scientist Training Program at Columbia University, in computational neuroscience. He completed psychiatry training at Columbia University/New York State Psychiatric Institute and a NIDA funded T32 research fellowship in Addiction Psychiatry at Columbia. Dr. Luo's current research interest lies at the interface of statistics, artificial intelligence, neuroscience and addiction psychiatry. Active research projects focus on bottom-up and top-down approaches to develop new algorithms and models to better match patients with substance use disorders to treatment. There is also significant interest in developing novel biomarkers and signal processing methods to extract predictive information from neuroscience-inspired human research methods.
Symposium II (continued)

Laura Brandt, Ph.D., Presenter
Dr. Brandt’s professional training unfolded through theoretical and clinical psychology training at the University of Vienna, a doctoral degree in Applied Medical Science at the Medical University of Vienna and postdoctoral training in transfer and implementation science. Simultaneously, her research has evolved from observational/descriptive accounts of the psychiatric burden as well as gender-specific aspects of addiction to exploring new and improved intervention approaches and simultaneously developing implementation strategies.

In her current position as Research Scientist II at the New York State Psychiatric Institute and Assistant Professor in Neurobiology (in Psychiatry) at Columbia University she is working with the National Institute on Drug Abuse Clinical Trials Network and a team of data scientists to empirically identify and validate surrogate treatment outcomes for opioid use disorder. Using her background in implementation research, she hopes to establish cross-national standards for measuring opioid use disorder treatment response that are useful for researchers and acceptable to patients, clinicians, policy makers and regulatory agencies.

Sandra Springer, M.D., Presenter
Dr. Sandra Springer is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. In addition, she is an attending Infectious Disease Physician at the VA Connecticut Healthcare System and the Director of the Infectious Disease Clinic at the Newington VA Site. She has significant clinical and research experience with persons with HIV and substance use disorders (SUDs) and is Board Certified in Internal Medicine, Infectious Disease and Addiction Medicine. She is the Director of her research program INSTRIDE (Integrating Substance Use Treatment Research with Infectious Disease for Everyone) at Yale School of Medicine where she and her team conduct clinical research on the integration of SUDS and Infectious Disease/HIV Treatments. In particular, she has focused on evaluating medication treatments for opioid and alcohol use disorders to improve substance use and ID/HIV treatment for persons involved with the criminal justice system. She currently is a principal investigator on 6 NIH awards and 1 VA Cooperative Studies Award. These awards include research evaluating the: impact of medication treatment for OUD on Immunobiological Outcomes and HIV latency; as well as randomized controlled trials evaluating the impact of long-acting injectable buprenorphine and naltrexone among persons with OUD released from prison and jail, among hospitalized patients with comorbid infections, and among veterans with OUD. She has presented her research numerous times both nationally and internationally and has published over 100 manuscripts and book chapters.

Gabriel Odom, Ph.D., Th.D., Presenter
Gabriel Odom is a data scientist, biostatistician, and statistical geneticist with a primary faculty appointment in Florida International University's Stempel College of Public Health and a voluntary appointment at the University of Miami's Miller School of Medicine. His research areas include genetics, genomics, epigenomics, and multi-omics; open-source software development; and curating data science methodology as applied to large clinical trials, population survey/census, and electronic medical records data. He is also an ordained (Eastern-Rite) Catholic priest.
Edward Nunes, M.D., Discussant

Dr. Nunes is Professor of Psychiatry at Columbia University Medical Center and New York State Psychiatric Institute (NYSPI), Multiple PI of the Greater New York Node of the Nida Clinical Trials Network (CTN), and Co-Director of the Chosen Center at Columbia University. He is a practicing psychiatrist board certified in Addiction Psychiatry and Addiction Medicine. He has devoted his career to research on the treatment of opioid, cocaine and other substance use disorders and is nationally and internationally recognized for his work on the evaluation and treatment of co-occurring depression and other psychiatric disorders among patients with substance use disorders and the development of pharmacological and behavioral treatments for substance use disorders, as well as for his work in the CTN testing the effectiveness of behavioral and pharmacological treatments in community-based treatment settings. Dr. Nunes has extensive experience with the design, conduct and analysis of clinical trials of treatments for opioid use disorder, including technology-based interventions and extended-release injections and implants of Buprenorphine and Naltrexone.

Landhing Moran, Ph.D., Discussant

Landhing Moran is a Health Scientist Administrator at the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Center for Clinical Trials Network (CCTN). She serves as a scientific officer for Multi-Site Clinical Research Projects on Substance Use Disorder treatments, including protocols studying HIV prevention and testing and other comorbid conditions, long-term follow-up on treatment outcomes, and secondary data analyses. She also coordinates a CCTN initiative to develop standardized treatment outcome measures for use in clinical trials. Prior to joining CCTN, Landhing was a IRTA Postdoctoral Fellow in the Clinical Pharmacology & Therapeutics Branch, Treatment Section and in the Office of the Clinical Director at the NIDA Intramural Research Program (IRP). While at NIDA-IRP, she used ecological momentary assessment collected via smartphone to study predictors of craving and substance use for people receiving medication for opioid use disorder, for those not seeking treatment, and for HIV-positive individuals and their social networks. She received her Ph.D. in Experimental Psychology from the University of South Carolina, Columbia.

Roger Weiss, M.D., Discussant

Roger D. Weiss, M.D., is Professor of Psychiatry at Harvard Medical School and Chief of the Division of Alcohol, Drugs, and Addiction at Mclean Hospital in Belmont, Massachusetts. His Career Has Focused on Treatment and Clinical Research with Substance-Dependent patients, Particularly Those with Co-Occurring Psychiatric Illness. He Has Been Principal Investigator on Numerous Nida or Niaaa grants, and Has Developed Integrated Group Therapy, an Evidence-Based Treatment for Patients with Co-Occurring Bipolar Disorder and Substance Use Disorders. Dr. Weiss Recently Led a Multi-Site National Study of the Treatment of Prescription Opioid dependence, as Part of the Nida Clinical Trials Network. He Has Authored over 400 Articles and Book Chapters as Well as 4 books, is a Member of Numerous Journal Editorial boards, and Has Participated in a Number of Prominent National committees, including Serving as vice Chair of the American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders. He Also Has Served as Substance Use Consultant to the Boston Red Sox. He Was Named a Member of Honor by the Spanish Society for Dual Disorders in 2011, and Has Received Numerous Other awards, including the H. David Archibald Award for Outstanding Research and/or Practice in the Addictions from the Centre for Addiction and Mental Health in Toronto (2007), the Jack H. Mendelson Research Award from Mclean Hospital (2012), the Dan Anderson Research Award from the Hazelden Foundation (2012), and the Anne M. Cataldo Excellence in Mentoring Award from Mclean Hospital (2014).
Medical Update

Transgender Medicine
Friday, December 9, 2022, 11:15 AM – 12:30 PM

Joshua Safer, M.D., FACP

Joshua Safer is the Executive Director of the Mount Sinai Center for Transgender Medicine and Surgery in New York City and Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Safer co-authored the Endocrine Society transgender medical care guidelines along with the most recent reviews of transgender medicine in both the New England Journal of Medicine and Annals of Internal Medicine. Dr. Safer is the medical curriculum lead for the Global Education Institute for the World Professional Association for Transgender Health (WPATH) and a member of WPATH’s Standards of Care revision committee. In addition, Dr. Safer co-authors the transgender hormone section for UpToDate. Dr. Safer was the inaugural president of the United States Professional Association for Transgender Health (USPATH). He has also advised a diverse array of institutions with regard to transgender medical care including the United States military, the International Olympic Committee, and World Athletics.

Symposium III

Inequities in Substance Use Treatment for Marginalized Communities: Challenges and Opportunities
Friday, December 9, 2022, 9:00 AM – 11:00 AM

Untreated substance use disorders contribute to thousands of deaths each year. Although there are treatments available, many communities have not accessed them. The reasons for this are multifactorial including stigma, mistrust, discrimination, racism and criminalization of substance use. Although many acknowledge substance use as the number one health problem in North America, data reveals that treatment gaps are enormous. In 2018, only 18% of people identified as needing treatment actually received it. These gaps are greater for marginalized communities. For Black and Latinx groups in the US, 90% and 92%, respectively, diagnosed with a SUD did not receive addiction treatment. Data from the 2018 National Survey on Drug Use and Health (NSDUH), suggests that substance use patterns reported by LGBTQ+ adults (in this survey, included individuals who describe themselves as lesbian, gay, or bisexual) are higher compared to those reported by non LGBTQ+ communities. This presentation will highlight the inequities in substance use treatment for Black, Latinx and LGBTQ+ populations, discuss approaches for engaging marginalized population and provide strategies for assessing, diagnosing and treating substance use disorders in marginalized communities.
Symposium III
Inequities in Substance Use Treatment for Marginalized Communities: Challenges and Opportunities

Friday, December 9, 2022, 9:00 AM – 11:00 AM

Michelle P. Durham, MD, MPH, FAPA, Chairperson and Moderator

Michelle P. Durham is the Vice Chair of Education in the Department of Psychiatry at Boston University School of Medicine (BUSM)/Boston Medical Center (BMC). She is a Board Certified Physician Specializing in Pediatric and Adult Psychiatry with Additional Board Certification in Addiction Medicine. Dr. Durham practices clinically at BMC and is a Clinical Associate Professor of Psychiatry and Pediatrics at BUSM. Her public health and clinical roles have always been in marginalized communities. She is dedicated to health equity and advocacy for equitable Mental Health Treatment Globally and Locally. Her research focuses on workforce development that reflects groups historically excluded from medicine, Training and Education for both the Pediatric Workforce and Mental Health Professionals. She is the Director of Clinical Training for the BMC Transforming and Expanding Access to Mental Health in Urban Pediatrics (TEAM UP) Grant Funded Initiative to bring mental health care into the Pediatric Primary Care Setting in Federally Qualified Community Health Centers. through the TEAM UP Initiative. She is the Principal Investigator for Three Federally Funded grants: HRSA Maternal and Child Health Collaborative Office Rounds, HRSA Achieving Culturally Competent and Equitable Substance Use Services (ACCESS) Training Program and SAMHSA (Services for Trauma and Resources) for Families. She is Involved at the state and national Level in the Massachusetts Psychiatric Society, American Psychiatric Association and American Academy of Child and Adolescent Psychiatry to Improve the standard of care for adults, children and adolescents.

Anita Bradley, M.S.W., Presenter

Anita Bradley is the Founder and Executive Director of the Northern Ohio Recovery Association (NORA). She is a graduate of Kent State and Cleveland State Universities. She earned a bachelor’s degree in Criminal Justice Studies and a master’s degree respectively. Bradley founded NORA in 2004 to prevent the use of alcohol, tobacco and other drugs utilizing a holistic healing and recovery approach. Bradley has been in recovery for over 25 years, blending personal and professional knowledge, in her approach. Anita has served as clinician and administrator, receiving numerous local leadership and volunteer service awards. U.S. presidential administration under Barack Obama called on her to lend expertise on substance abuse and prevention. Anita is the winner of smart business magazine’s women who excel entrepreneur award; winner of the Joel Hernandez Community
Fabiola Arbelo-Cruz, M.D., Presenter

Dr. Fabiola Arbelo-Cruz (she/her/hers) is an Attending Addiction Psychiatrist at the Connecticut Mental Health Center (CMHC) in New Haven, CT, and Assistant Professor of Psychiatry at Yale School of Medicine. One of her roles at CMHC includes working with the Street Psychiatry team, a model of mental health and addiction care delivery that takes physicians and other providers to the streets to provide care primarily to people who are experiencing unsheltered homelessness.

Dr. Arbelo Cruz graduated magna cum laude with a bachelor’s in science degree from the University of Puerto Rico and received her medical degree from the Ponce Health Sciences University School of Medicine. She completed general psychiatry residency at Boston Medical Center and was awarded the Chairman’s Award (the highest honor for a graduating resident in the BMC program) as she exceeded expectations in every domain—interpersonally, clinically, research, and humanism. Dr. Arbelo Cruz also completed an Addiction Psychiatry Fellowship at Yale.

Dr. Arbelo Cruz is the past recipient of the APA Travel Scholarship for Minority Medical Students and the Externship in Addiction Psychiatry Award, and AAAP John Renner award in 2021. She was accepted to the Yale REACH Scholar Program—a program aimed to adequately train physicians to work with minority patients with co-occurring mental health and substance use disorders.

Daryl Shorter, M.D., Presenter

Dr. Daryl Shorter is a Diplomate of the American Board of Psychiatry and Neurology and is Board Certified in both General and Addiction Psychiatry. A Graduate of Rice University and Baylor College of Medicine, Dr. Shorter completed general psychiatry residency at the Ohio State University Medical Center and Addiction Psychiatry Fellowship at New York University/Langone Medical Center. Dr. Shorter is an Associate Professor in the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine. He also serves as the Medical Director of Addictions and Recovery Services at the Menninger Clinic as well as the Program Director of the BCM Addiction Psychiatry Fellowship. Dr. Shorter is the author of numerous peer-reviewed publications and book chapters focusing on medication treatment of substance use disorders and addictions training in Graduate Medical Education and lectures widely on topics related to the LGBTQ+ Community.
Workshops

**Thursday, December 8, 1:30PM - 3PM - Concurrent Workshop Session A**

A1: Early Lessons Learned About The Use of Injectable Long-Acting Buprenorphine in Persons Hospitalized with Infections and Opioid Use Disorder

A2: Substance Use Disorder Measurement Based Care in Behavioral Health

A3: Evidence-Based Practices for Treatment of Methamphetamine Dependency: A Review

A4: Addiction and Family Court: Walking the Legal Tightrope

A5: Incorporating Addiction Treatments Into General Psychiatric Settings

**Friday, December 9, 2PM - 3:30PM - Concurrent Workshop Session B**

B1: How to Interpret Urine Test Results and Identify Manipulation in Buprenorphine Treatment Program: Case Studies on Buprenorphine Dose and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program

B2: Management of Alcohol Use Disorders in the Liver Transplant Population

B3: Induction Without Withdrawal: Buprenorphine/Naloxone Micro-Dosing

B4: Reducing Harm From Substance Use: Motivational Interviewing and Harm Reduction

B5: Contrasting Tools for the Concurrent Treatment of PTSD and SUD: Prolonged Exposure and MDMA-Assisted Therapy

**Saturday, December 10, 10:15AM-11:45AM - Concurrent Workshop Session C**

C1: Journeys End, Journeys Begin: An Exploration Into Alternative Therapeutic Approaches in Substance Use Disorders

C2: Implementation and Clinical Challenges of SUBLOCADE Treatment

C3: Harnessing Your Expertise: AAAP Media Training with Reporting on Addiction

C4: Value Based Care in Addictions Treatment

C5: To Infinity and Beyond! Innovative Strategies to Enhance Addiction Psychiatry Education in General Psychiatry Residency Programs
John Renner Awardees

Medical Students

Melvin Rico, BS
David Geffen School of Medicine at UCLA

John Messinger, BS
Harvard Medical School

Serra Sozen, BA
The Robert Larner, M.D. College of Medicine at The University of Vermont

Emily Rao, BA
University of California, San Diego

Brandon Lew, BA
University of Nebraska Medical Center

Kira Panzer, BA
Duke University School of Medicine

Olivia Kay Murray, BA
Indiana University School of Medicine

PGY I-IV:

Sean Lynch, MD
Mount Sinai Beth Israel

Justin Morales, MD
NYU General Psychiatry Residency

Sravan Narapureddy, MD
UT Southwestern - Psychiatry Residency
John Renner Awardees

PGY I-IV:

Sean Barrett, DO
Broadlawns-Unity Point Psychiatry Residency

Nicholas Boswell, MD
UT Southwestern Medical Center Psychiatry Residency

Caitlyn Fitzgerald, MD
Gateway BHS

Sophia Array, MD
University of Florida

Tyler Torrico, MD
Kern Medical

Deborah Rose, MD
Duke University Medical Center

Geoffrey Russell, MD
Renaissance School of Medicine at Stony Brook University

Rachel Gluck, MD
Emory University General Psychiatry

Sonya Bakshi, MD
NYU Langone
John Renner Awardees

PGY I-IV:

Siddhi Bhivandkar, MD
St. Elizabeth’s Medical Center

Julian Raffoul, MD, PhD
Vanderbilt Psychiatry and Behavioral Sciences

Ryan Slauer, MD
Duke University

PGY V/Fellows

Muhammad Aadil, MD
Yale School of Medicine

Amber Edinoff, MD
Massachusetts General/ Brigham and Women/ McLean/ Harvard Medical School

Daniel Tuinstra, MD
Michigan State University/Pine Rest

Andrew Lee, MD
Medical University of South Carolina

David Martinez Garza, MD
Mass General Brigham/Harvard Medical School

Karuna Thomas
University of Massachusetts (UMass Chan Medical School)
John Renner Awardees

PGY V/Fellows

Chenghui Su, DO
New York University Addiction Psychiatry Fellowship

Nicholas Bormann, MD
Indiana University Addiction Psychiatry Fellowship

Aaron Quiggle, MD
Mass General Brigham, Addiction Psychiatry Fellowship Program

Jacob Buinewicz, MD
Thomas Jefferson University Hospital

Research Award

Jeremy Weleff, DO
Yale School of Medicine

International Award

Priyanka Saha, MD
All India Institute of Medical Sciences, New Delhi
Sheldon Miller Early Career Award

Nia Harris, MD
New York Presbyterian/Weill Cornell Medical Center

Marcus Hughes, MD
Howard University College of Medicine/Howard University Hospital

Henry Onyeaka, MD, MPH
Massachusetts General Hospital/McLean Hospital Adult Psychiatry Residency Program

Regional Award

Aniket Malhotra
Emory University

Ashley Warnock, MD, MSc
University of Toronto

Adeolu Oladunjoye, MD, MPH
Baylor College of Medicine

Eric Parmon, MD
UT Health San Antonio

Mary Ashley Mercer, MD
Gateway Behavioral Health CSB
Regional Award

Samantha Perez, DO
University of Michigan Hospitals

Eric Dobson, MD
Medical University of South Carolina

Under-Represented Minority Award

Addiction Psychiatry Fellows

Frantz Aubry, MD
Thomas Jefferson University

Jason Barrett, MD
Indiana University School of Medicine

Michael Hsu, MD
Emory School of Medicine

Virginia Medinilla, MD, PhD
University of Wisconsin - Madison Addiction Psychiatry Fellowship

Aitzaz Munir, MBBS,MD
NYU Langone Health Grossman School of Medicine Addiction Psychiatry Fellowship

Olusegun Popoola, MD, MPH
Baylor College of Medicine
Under-Represented Minority Award

Medical Students

Sebastian Acevedo, BA
New Jersey Medical School

Caylon Pettis, BS
Loyola University Chicago Stritch School of Medicine

Diego Regalado, BS
Texas Tech University Health Science Center

Residents PGY I-IV

Raheel Chaudhry, MD
Baylor College of Medicine

Andrea Guerrero Cignarella, MD
Psychiatry Rutgers NJMS

Adeolu Ilesanmi, MD
New York Presbyterian/Weill Cornell Medical College

Kristen Laster, MD
Baylor College of Medicine

Jose Perez Martell, MD
University of Kansas Medical Center

Francis Nguyen, DO
LSUHSC New Orleans General Psychiatry
Under-Represented Minority Award
Residents PGY I-IV

Stanley Nkemjika, MD, MPH
Psychiatry Residency Interfaith Medical Center

Laura Oyugi, MD
Broadlawns Medical Center UnityPoint Health
Psychiatry residency program

Terence Tumenta, MD, MPH
One Brooklyn Health at Interfaith Medical Center

Olivetta Uradu, MD
Yale University

Award for Medical Student Education

Lakshit Jain
Connecticut Valley Hospital

Award for Residency Education

William Jangro
Thomas Jefferson University